Plasma phospholipid transfer protein activity is lowered by 24-h insulin and Acipimox administration: Blunted response to insulin in type 2 diabetic patients

Diabetes

Volumn 48, Issue 8, 1999, Pages 1631-1637

  Riemens, Stephen C ^a   Van Tol, Arie ^b   Sluiter, Wim J ^a   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; APOLIPOPROTEIN A1; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RASH; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTILIPEMIC AGENTS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; DIABETES MELLITUS, TYPE 2; GLYCOPROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PHOSPHOLIPID TRANSFER PROTEINS; PYRAZINES; REFERENCE VALUES; TIME FACTORS;

EID: 0032810957     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.8.1631     Document Type: Article

References (54)

1. Dullaart RPF, Groener JEM, Erkelens DW: Cholesteryl ester transfer between lipoproteins. Diabetes Nutr Metab 14:329-343, 1991
2. Tall AR: Plasma cholesteryl ester transfer protein. J Lipid Res 34:1255-1274, 1993
3. Jauhiainen M, Metso J, Pahlman R, Blomqvist S, Van Tol A, Ehnholm C: Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 268:4032-4036, 1993
4. Tu AY, Nishida HI, Nishida T: High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J Biol Chem 268: 23098-23105, 1993
5. Bruce C, Tall AR: Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis. Curr Opin Lipidol 6:306-311, 1995
6. Barter PJ, Rye KA: Molecular mechanisms of reverse cholesterol transport. Curr Opin Lipidol 7:82-87, 1996
7. Tall AR, Krumholz S, Olivecrona T, Deckelbaum RJ: Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J Lipid Res 26:842-851, 1985
8. Tollefson JH, Ravnik S, Albers JJ: Isolation and characterization of a phospholipid transfer protein (LTP-II) from human plasma. J Lipid Res 29: 1593-1602, 1988
9. Speijer H, Groener JEM, Van Ramshorst E, Van Tol A: Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 90:159-168, 1991
10. Riemens SC, Van ToI A, Sluiter WJ, Dullaart RPF: Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 140:71-79, 1998
11. Lusa S, Jauhiainen M, Metso J, Somerharju P, Ehnholm C: The mechanism of plasma lipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion. Biochem J 313:275-282, 1996
12. Lagrost L, Athias A, Herbeth B, Guyard-Dangremont V, Artur Y, Paille F, Gambert P, Lallemant C: Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. Physiological relevance in alcoholic patients. J Biol Chem 271:18058-19065, 1996
13. Rye KA, Jauhiainen M, Barter PJ, Ehnholm C: Triglyceride-enrichment of high density lipoproteins enhances their remodeling by phospholipid transfer protein. J Lipid Res 39:613-622, 1998
14. Castro GR, Fielding CJ: Early incorporation of cell-derived cholesterol into pre-beta-migrating high density lipoprotein. Biochemistry 27:25-29, 1988
15. 1-HDL. Biochim Biophys Acta 1301:255-262, 1996
16. Syvänne M, Castro G, Dengremont C, De Geitere C, Jauhiainen M, Ehnholm C, Michelagnoli S, Franceschini G, Kahri J, Taskinen MR: Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer assay. Atherosclerosis 127:245-253, 1996
17. Sutherland WH, Walker RJ, Lewis-Barned NJ, Pratt H, Tillman HC: The effect of acute hyperinsulinemia on plasma cholesteryl ester transfer protein activity in patients with non-insulin-dependent diabetes mellitus and healthy subjects. Metabolism 43:1362-1366, 1994
18. Arii K, Suehiro T, Yamamoto M, Ito H, Hashimoto K: Suppression of plasma cholesteryl ester transfer protein activity in acute hyperinsulinemia and effect of plasma nonesterified fatty acid. Metabolism 46:1166-1170, 1997
19. Van Tol A, Ligtenberg JJM, Riemens SC, Van Haeften TW, Reitsma WD, Dullaart RPF: Lowering of plasma phospholipid transfer protein activity by acute hyperglycaemia-induced hyperinsulinaemia in healthy men. Scand J Clin Lab Invest 57:147-158, 1997
20. Riemens SC, Van Tol A, Sluiter WJ, Dullaart RPF: Plasma phospholipid transfer protein activity is related to insulin resistance and altered free fatty acid and triglycerides: impaired acute lowering by insulin in obese type II diabetic patients. Diabetologia 41:929-934, 1998
21. Dullaart RPF, Hoogenberg K, Dikkeschei LD, Van Tol A: Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. Arterioscler Thromb 14:1581-1585, 1994
22. Mero N, Van Tol A, Scheek LM, Van Gent T, Labeur C, Rosseneu M, Taskinen MR: Decreased postprandial high density lipoprotein cholesterol and apolipoproteins A-I and E in normolipidemic smoking men: relations with lipid transfer proteins and LCAT activities. J Lipid Res 39:1493-1502, 1998
23. Jones DY, Judd JT, Taylor PR, Campbell WS, Nair PP: Menstrual cycle effect on plasma lipids. Metabolism 37:1-2, 1988
24. National Diabetes Data group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979
25. 2 cholesterol level in older adults. N Engl J Med 322: 229-234, 1990
26. Jensen MD, Heiling VJ: Heated hand vein blood is satisfactory for measurements during free fatty acid kinetic studies. Metabolism 40:406-409, 1991
27. Demacker PN, Hijmans AG, Vos-Janssen HE, Van't Laar A, Jansen AP: A study of the use of polyethylene glycol in estimating cholesterol in high-density lipoprotein. Clin Chem 26:1775-1779, 1980
28. Hindriks FR, Wolthers BG, Groen A: The determination of total cholesterol in serum by gas-liquid chromatography compared with two other methods. Clin Chim Acta 74:207-215, 1977
29. Dullaart RPF, Sluiter WJ, Dikkeschei LD, Hoogenberg K, Van Tol A: Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 24:188-194, 1994
30. Hannuksela M, Marcel YL, Kesäniemi YA, Savolainen MJ: Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J Lipid Res 33:737-744, 1992
31. Bagdade JD, Lane JT, Subbaiah PV, Otto ME, Ritter MC: Accelerated cholesteryl ester transfer in noninsulin-dependent diabetes mellitus. Atherosclerosis 104:69-77, 1993
32. Kahri J, Syvänne M, Taskinen MR: Plasma cholesteryl ester transfer protein activity in non-insulin-dependent diabetic patients with and without coronary artery disease. Metabolism 43:1498-1502, 1994
33. Coppack SW, Jensen MD, Miles JM: In vivo regulation of lipolysis in humans. J Lipid Res 35:177-193, 1994
34. Lewis GF, Uffelman KD, Szeto LW, Steiner G: Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apo B production in normal weight and obese individuals. Diabetes 42:833-842, 1993
35. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G: Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 95:158-166, 1995
36. Malmström R, Packard CJ, Watson TDG, Rannikko S, Caslake M, Bedford D, Stewart P, Yki-Järvinen H, Shepherd J, Taskinen MR: Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 17:1454-1464, 1997
37. Christie AW, McCormick DKT, Emmison N, Kraemer FB, Alberti KGMM, Yeaman SJ: Mechanism of anti-lipolytic action of acipimox in isolated rat adipocytes. Diabetologia 39:45-53, 1996
38. Malmström R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Järvinen H, Shepherd J, Taskinen MR: Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes 47:779-787, 1998
39. Malmström R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Järvinen H, Shepherd J, Taskinen MR: Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40:454-462, 1997
40. Che YD, Golay A, Swislocki ALM, Reaven GM: Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:17-21, 1987
41. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA: Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus. J Clin Invest 84:205-213, 1989
42. Skowronski R, Hollenbeck CB, Varasteh BB, Chen YDI, Reaven GM: Regulation of non-esterified fatty acid and glycerol concentration by insulin in normal individuals and patients with type 2 diabetes. Diabet Med 81:330-333, 1991
43. Jiang X, Bruce C: Regulation of murine plasma phospholipid transfer protein activity and mRNA levels by lipopolysaccharide and high cholesterol diet. J Biol Chem 270:17133-17138, 1995
44. Albers JJ, Tu AY, Wolfbauer G, Cheung MC, Marcovina SM: Molecular biology of phospholipid transfer protein. Curr Opinion Lipidol 7:88-93, 1996
45. Yki-Järvinen H, Taskinen MR, Koivisto VA, Nikkilä EA: Response of adipose tissue lipoprotein lipase activity and serum lipoproteins to acute hyperinsulinaemia in man. Diabetologia 27:364-369, 1984
46. Wor D, Henriksen JE, Vaag A, Thye-Ronn P, Melander A, Beck-Nielsen H: Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period. J Clin Endocrinol Metab 78:717-721, 1994
47. Taskinen MR, Nikkilä EA: Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia. Atherosclerosis 69:249-255, 1988
48. Davoren PM, Kelly W, Gries FA, Hubinger A, Whately-Smith C, Albert KGMM: Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus. Metabolism 47:250-256, 1998
49. Sirtori CR, Gianfranceschi G, Sirtori M, Bernini F, Descovich G, Montaguti U, Fuccella LM, Musatti L: Reduced triglyceridemia and increased high density lipoprotein cholesterol levels after treatment with acipimox, a new inhibitor of lipolysis. Atherosclerosis 38:267-271, 1981
50. Eisenberg S: High density lipoprotein metabolism. J Lipid Res 25:1017-1058, 1984
51. Mann CJ, Yen FT, Grant AM, Bihain BE: Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 88:2059-2066, 1991
52. Baynes C, Henderson AD, Richmond W, Johnston DG, Elkeles RS: The response of hepatic lipase and serum lipoproteins to acute hyperinsulinaemia in type 2 diabetes. Eur J Clin Invest 22:341-346, 1992
53. Nishida HI, Nishida T: Phospholipid transfer protein mediates transfer of not only phosphatidylcholine but also cholesterol from phosphatidylcholine-cholesterol vesicles to high density lipoproteins. J Biol Chem 272:6959-6964, 1997
54. Jiang X, Francone OL, Bruce C, Milne R, Mar J, Walsh A, Breslow JL, Tall AR: Increased preβ-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest 96:2373-2380, 1996